CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 21 enrolled
Drug / intervention
micafungin +2 moredrug
Likely dose
micafungin 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00839540
NCT00839540Phase 4Completed
CompareCT.gov

Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins in Patients With Presumptive Candidemia

Gary E. Stein, Pharm.D.·interventional·Posted Feb 9, 2009·Updated Apr 30, 2024

In Brief

A Phase 4 clinical trial evaluating micafungin, Micafungin, and 1 other intervention for Candidemia. Completed, enrolled 21 participants across 1 site.

Detailed Summary

The purpose of this pharmacokinetic (PK) and pharmacodynamic (PD) study is: To study the rate and duration of serum cidal activity of caspofungin (CFG) and micafungin (MFG) against Candida isolates from the subject and against Candida glabrata with varying degrees of caspofungin susceptibilities. This investigation will provide clinicians information supporting the use of caspofungin and micafungin in situations where Candida strains may be a cause of infection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCandidemia
CountriesUnited States
CollaboratorsAstellas Pharma US, Inc.

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 9, 2009
Enrollment StartDec 1, 2008
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.4 years ago

Interventions

micafungindrug

100 mg qd by slow IV infusion for 24 h

Micafungindrug

200 mg qd by slow IV infusion for 24 h

Caspofungindrug

70 mg LD followed by 50 mg qd by slow IV infusion for 24 h